1.华润三九现代中药制药有限公司,广东省惠州市惠城区南岸路199号,516000
2.华润三九医药股份有限公司
3.广州中医药大学第一附属医院
4.广州循证医药科技有限公司
yang_zhongqi@163.com
收稿:2026-01-20,
修回:2026-08-30,
录用:2026-08-19,
纸质出版:2026-10-17
移动端阅览
吴成凤,唐雅琴,李丹等.中药配方颗粒临床用药情况及安全性的大规模观察性集中监测[J].中医杂志,2026,67(20):2187-2194.
WU Chengfeng,TANG Yaqin,LI Dan,et al.A Large-Scale Observational Centralized Monitoring Study on the Clinical Use and Safety of Traditional Chinese Medicine Formula Granules[J].Journal of Traditional Chinese Medicine,2026,67(20):2187-2194.
吴成凤,唐雅琴,李丹等.中药配方颗粒临床用药情况及安全性的大规模观察性集中监测[J].中医杂志,2026,67(20):2187-2194. DOI: 10.13288/j.11-2166/r.2026.20.008.
WU Chengfeng,TANG Yaqin,LI Dan,et al.A Large-Scale Observational Centralized Monitoring Study on the Clinical Use and Safety of Traditional Chinese Medicine Formula Granules[J].Journal of Traditional Chinese Medicine,2026,67(20):2187-2194. DOI: 10.13288/j.11-2166/r.2026.20.008.
目的
2
基于真实世界数据评价中药配方颗粒的安全性特征及临床使用现状,为其合理应用提供依据。
方法
2
采用多中心、前瞻性、开放性、观察性集中监测设计,纳入2020年2月5日至2025年5月20日全国293家医疗机构使用中药配方颗粒的患者,以数据收集年份作为分层因素,提取患者的基本信息(包括性别、年龄、合并用药情况等)、中药配方颗粒用药信息(平均处方用量、不合理使用情况等)、不良事件/不良反应发生情况及相关因素,并进行统计分析。
结果
2
安全数据集(SS)共纳入42 011例患者,平均年龄(38.34±22.30)岁,男性18 693例、女性23 318例。3519例(8.38%)患者存在既往或合并疾病,排前3位的为高血压病(1189例,33.79%)、糖尿病(850例,24.15%)、冠心病(471例,13.38%);纳入患者中诊断排名前3位的为呼吸系统疾病、胸及纵隔疾病(7008例,16.68%),感染及侵染类疾病(6591例,15.69%),胃肠系统疾病(4580例,10.90%);在41 961例有合并用药记录的患者中,3332例(7.94%)患者存在合并用药,其中2819例(6.72%)联合使用西药。中药配方颗粒平均处方用量(用量为饮片剂量,下同)2020年(158.23±104.86)g、2021年(131.70±65.84)g、2022年(130.62±59.96)g、2023年(86.74±50.61)g、2024年(118.59±52.01)g、2025年(134.38±49.43)g。毒性品种使用频率最高的前5位中药分别是苦杏仁(2746例,6.54%)、细辛(2193例,5.22%)、燀苦杏仁(862例,2.05%)、白屈菜(747例,1.78%)、吴茱萸(645例,1.54%)。存在“十八反”“十九畏”配伍禁忌的中药配方颗粒使用以2020年发生例数最多(54例,0.503%),此后显著下降,总体保持零发生或极低水平。中药配方颗粒不良反应总体发生率为0.057%(24例),属罕见水平,其中2020年为0.028%(3例)、2021年和2022年为0、2023年为0.065%(5例)、2024年为0.158%(15例)、2025年为0.226%(1例)。24例发生不良反应的患者中,15例存在不合理使用情况;24例中使用毒性品种的5例,且均存在不合理使用情况。多因素Logistic回归分析显示,无既往药物不良反应[OR=0.053,95%CI(0.006,0.465)]、无合并用药[OR=0.315,95%CI(0.109,0.911)]与较低的不良反应风险相关。
结论
2
中药配方颗粒在临床中使用广泛,总体安全性良好,今后临床应加强对既往药物不良反应与合并用药患者的管理,以进一步提高用药安全性。
Objective
2
To evaluate the safety and clinical utilization of traditional Chinese medicine (TCM) formula granules based on real-world data, and to provide evidence for their rational clinical use.
Methods
2
A multicenter, prospective, open-label, observational centralized monitoring study was conducted. Participants who received TCM formula granules in 293 medical institutions throughout China from February 5th, 2020 to May 20th, 2025 were consecutively enrolled. The year of data collection was used as the stratification factor. Demographic characteristics (including sex, age, and concomitant medication use), information on TCM formula granule use (including mean prescribed dosage and inappropriate use), and adverse event(AE)/adverse drug reaction(ADR) occurrence and related factors were collected and statistically analyzed.
Results
2
A total of 42 011 participants were included in the safety set (SS), with a mean age of (38.34±22.30) years, including 18 693 males and 23 318 females. Among them, 3519 participants (8.38%) had a history of or concomitant diseases. The three most common comorbidities were hypertension (1189 cases, 33.79%), diabetes mellitus (850 cases, 24.15%), and coronary heart disease (471 cases, 13.38%). The top three diagnostic categories were respiratory, thoracic, and mediastinal diseases (7008 cases, 16.68%), infectious and parasitic diseases (6591 cases, 15.69%), and gastrointestinal diseases (4580 cases, 10.90%).Among 41 961 participants with available concomitant medication data, 3332(7.94%) received concomitant medications, and western medicines were the most commonly used concomitant medications (2819 cases, 6.72%). The mean prescribed dosage of TCM formula granules (expressed as the equivalent dosage of crude herbal pieces) was (158.23±104.86) g in 2020, (131.70±65.84) g in 2021, (130.62±59.96) g in 2022, (86.74±50.61) g in 2023, (118.59±52.01) g in 2024, and (134.38±49.43) g in 2025. The five most frequently prescribed toxic herbs were Kuxingren (
Semen Armeniacae Amarum,
2746 cases, 6.54%), Xixin (
Radix et Rhizoma Asari,
2193 cases, 5.22%), processed Kuxingren (862 cases, 2.05%), Baiqucai (
Herba Chelidonii,
747 cases, 1.78%), and Wuzhuyu (
Fructus Evodiae,
645 cases, 1.54%). Prescriptions involving incompatible combinations of the "eighteen antagonisms" and the "nineteen mutual inhibitions" were most frequently observed in 2020 (54 cases, 0.503%), and then decreased markedly, remaining at zero or an extremely low level thereafter. The overall incidence of adverse drug reactions (ADRs)
associated with TCM formula granules was 0.057% (24 cases), indicating a rare occurrence. The annual incidence was 0.028% (3 cases) in 2020, 0 in both 2021 and 2022, 0.065% (5 cases) in 2023, 0.158% (15 cases) in 2024, and 0.226% (1 case) in 2025. Among the 24 patients who experienced ADRs, 15 had inappropriate medication use.Five of the 24 patients used toxic herbs, and all five had inappropriate medication. Multivariate logistic regression analysis showed that no history of drug-related adverse reactions [OR=0.053, 95%CI(0.006, 0.465)] and no concomitant medication [OR=0.315, 95%CI(0.109, 0.911)] were associated with a lower risk of ADRs.
Conclusion
2
TCM formula granules are widely used in clinical practice and exhibit a favorable overall safety. Greater attention should be paid to people with a history of drug-related adverse reactions and those receiving concomitant medications to further improve medication safety.
付红 , 陈小菲 , 吴瑞 , 等 . 中药配方颗粒国家标准在临床应用中的现状、问题及对策 [J]. 中医学报 , 2025 , 40 ( 1 ): 210 - 215 .
张伟 , 孙叶芬 , 金传山 , 等 . 中药配方颗粒研究现状与展望 [J]. 中草药 , 2022 , 53 ( 22 ): 7221 - 7233 .
杨国营 , 梁颖 , 曹俊岭 , 等 . 中药配方颗粒调剂技术规范专家共识(2022年版) [J]. 医药导报 , 2022 , 41 ( 8 ): 1079 - 1082 .
国家药典委员会 . 中华人民共和国药典(一部) [M]. 北京 : 中国医药科技出版社 , 2020 .
国家药典委员会 . 中华人民共和国药典(一部) [M]. 北京 : 中国医药科技出版社 , 2025 .
曹建恒 , 李国臣 , 殷莉 . 从“十八反”“十九畏”探讨中药配伍毒性来源 [J]. 中医学报 , 2025 , 40 ( 9 ): 1897 - 1900 .
曹烨 , 万邦喜 , 苏敏实 . 药物临床试验 安全评价:广东共识(2020年版) [J]. 今日药学 , 2020 , 30 ( 11 ): 731 - 740 .
Council for International Organizations of Medical Sciences . Guidelines for preparing core clinical-safety information on drugs: report of CIOMS Working Groups Ⅲ and V [M/OL]. 2nd Edition . Geneva : Council for International Organizations of Medical Sciences , 1999 . https://cioms.ch/publications/product/guidelines-preparing-core-clinical-safety-information-drugs-second-edition-report-cioms-working-groups-iii-v/#description https://cioms.ch/publications/product/guidelines-preparing-core-clinical-safety-information-drugs-second-edition-report-cioms-working-groups-iii-v/#description .
国家药品监督管理局 . 国家药监局关于发布《中药配方颗粒质量控制与标准制定技术要求》的通告2021年第16号 [EB/OL]. ( 2021-01-26 ) [ 2026-08-20 ]. https://www.nmpa.gov.cn/yaopin/ypggtg/20210210145453181.html https://www.nmpa.gov.cn/yaopin/ypggtg/20210210145453181.html .
T/CATCM 032-2024 中药配方颗粒临床使用指南 [S].
李成玉 , 谢兴元 . 某院2021—2022年呼吸科中药饮片使用与不良反应分析 [J]. 中医药管理杂志 , 2024 , 32 ( 4 ): 65 - 67 .
肖林 , 李晓杰 , 洪燕萍 , 等 . 中药配方颗粒有效性和安全性的Meta分析 [J]. 广东药科大学学报 , 2025 , 41 ( 3 ): 117 - 127 .
韩梅 , 夏芸 , 李雪梅 , 等 . 中药配方颗粒临床研究现状、疗效与安全性的概况性评价:以华润三九配方颗粒为例 [J]. 中医杂志 , 2021 , 62 ( 10 ): 861 - 867 .
李军 , 黄巧玲 . 中药配方颗粒与传统中药饮片治疗阴虚火旺型盗汗的效果观察 [J]. 婚育与健康 , 2023 , 29 ( 7 ): 100 - 102 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号